Rev Esp Quimioter 2017, 30(4):269-275
|Impact of 13-valent pneumococal conjugate polysaccharide vaccination on exacerbations rate of COPD patients with moderate to severe obstruction
JUAN MARCO FIGUEIRA-GONÇALVES, NATALIA BETHENCOURT-MARTÍN, LINA INMACULADA PÉREZ-MÉNDEZ, DAVID DÍAZ-PÉREZ, CRISTINA GUZMÁN-SÁENZ, PEDRO VIÑA-MANRIQUE, ARTURO JOSÉ PEDRERO-GARCÍA
Introduction. One of the major microorganisms described as the cause of exacerbations of chronic obstructive pulmonary disease (COPD) is Streptococcus pneumoniae. The aim of this study is to evaluate the impact of 13-valent pneumococcal conjugate polysaccharide vaccine (PCV13) in COPD patients with regard to the development of exacerbations and the possible differential effect according to the patient’s phenotype.
Rev Esp Quimioter 2017; 30(4):269-275 [pdf]